A plea for "Omics" research in complex diseases such as multiple sclerosis - A change of mind is needed

Journal of the Neurological Sciences

Volumn 222, Issue 1-2, 2004, Pages 3-5

  Martin, Roland ^a   Leppert, David ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER;

CLINICAL FEATURE; EDITORIAL; GENOMICS; HUMAN; MEDICAL RESEARCH; METABOLISM; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEOMICS; RNA TRANSCRIPTION;

BIOMEDICAL RESEARCH; COMPUTATIONAL BIOLOGY; DATABASES, NUCLEIC ACID; DRUG EVALUATION, PRECLINICAL; GENOMICS; HUMANS; META-ANALYSIS; MULTIPLE SCLEROSIS; PROTEOMICS;

EID: 3042746908     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2004.02.013     Document Type: Editorial

References (10)

1. The Multiple Sclerosis Genetics Group, Barcellos L.F., Oksenberg J.R., Green A.J., Bucher P., Rimmler J.B., Schmidt S., et al. Genetic basis for clinical expression in multiple sclerosis. Brain. 125:2002;150-158
2. Wiendl H., Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs. 16(3):2002;183-200
3. The Lenercept Multiple Sclerosis Study Group the University of British Columbia MS/MRI Analysis Group TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology. 53(3):1999;457-465
4. Panitch H.S., Hirsch R.L., Haley A.S., Johnson K.P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1(8538):1987 (Apr. 18);893-895
5. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8(5):2002 (May);500-508
6. Bomprezzi R., Ringner M., Kim S., Bittner M.L., Khan J., Chen Y., et al. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum. Mol. Genet. 12(17):2003 (Sep. 1);2191-2199
7. Whitney L.W., Ludwin S.K., McFarland H.F., Biddison W.E. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J. Neuroimmunol. 121(1-2):2001 (Dec. 3);40-48
8. Whitney L.W., Becker K.G., Tresser N.J., Caballero-Ramos C.I., Munson P.J., Prabhu V.V., et al. Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays. Ann. Neurol. 46(3):1999 (Sep.);425-428
9. Mycko M.P., Papoian R., Boschert U., Raine C.S., Selmaj K.W. cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain. 126:2003;1048-1057
10. GAMES (Genetic Analysis of Multiple Sclerosis in EuropeanS) the Transatlantic Multiple Sclerosis Genetics Cooperative A meta-analysis of whole genome linkage screens in multiple sclerosis. J. Neuroimmunol. 143(1-2):2003 (Oct.);39-46